Drugs / IPH5301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05143970 | Jan 2022 → Mar 2027 expected | breast cancer, endometrial cancer, esophageal cancer, gastric cancer +4 | Institut Paoli-Calmettes | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2019-05-23 | Innate Pharma | Results Innate Pharma announces publication on next generation immunotherapies targeting the adenosine pathway in “Cell Reports” innate-pharma.com ↗
In vitro and in vivo data support the use of anti-CD39 and anti-CD73 mAbs in combination cancer therapies. |
| 2019-04-01 | Innate Pharma | Results Innate Pharma highlights next generation of cancer immunotherapies at the American Association of Cancer Research (AACR) 2019 annual meeting innate-pharma.com ↗
New preclinical data highlights IPH5201 (anti-CD39) and IHP5301 (anti-CD73) neutralizing antibodies targeting the immunosuppressive adenosine pathway |
All press releases naming this drug 3 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPH5301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05143970 ↗ |